CSIMarket
 
Pfizer Inc  (NYSE: PFE)
 
Price: $28.8100 $-0.21 -0.724%
Day's High: $29.209999084472656 Week Perf: 3.04 %
Day's Low: $ 28.44 30 Day Perf: 11.62 %
Volume (M): 24,204,138 52 Wk High: $ 29.21
Volume (M$): $ 0 52 Wk Avg: $25.87
Open: $29.09 52 Wk Low: $23.58



 Market Capitalization (Millions $) 164,188
 Shares Outstanding (Millions) 5,699
 Employees 75,000
 Revenues (TTM) (Millions $) 63,696
 Net Income (TTM) (Millions $) 4,370
 Cash Flow (TTM) (Millions $) 66
 Capital Exp. (TTM) (Millions $) 2,416

Business Description


Company Profile: Pfizer Inc.

Overview:
Pfizer Inc. is a leading research-based global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative prescription medicines for both humans and animals. Additionally, Pfizer is well-known for its extensive portfolio of consumer healthcare products, which are trusted by millions around the world.

Incorporation:
Pfizer was incorporated under the laws of the State of Delaware on June 2, 1942. Since its inception, the company has grown to become one of the largest and most influential pharmaceutical companies in the world.

Mission and Vision:
Pfizers mission is to apply science and global resources to bring therapies to people that extend and significantly improve their lives. The company is committed to ensuring access to its innovative medicines and vaccines, fostering health equity and patient empowerment.

Key Areas of Focus:
Pfizer operates in various therapeutic areas, including but not limited to:

- Oncology: Developing treatments for various types of cancer.
- Vaccines: Notably recognized for its COVID-19 vaccine, as well as vaccines for other infectious diseases such as pneumococcal disease and meningitis.
- Cardiovascular Disease: Providing solutions for heart disease, hypertension, and related conditions.
- Immunology: Offering therapies for autoimmune diseases.
- Rare Diseases: Innovating treatments for conditions that affect a small population of patients.

Global Presence:
Pfizer operates in numerous countries worldwide, employing a diverse workforce committed to advancing healthcare. The company collaborates with healthcare professionals, governments, and academic institutions to address global health challenges.

Recent Achievements:
Pfizer has achieved significant milestones in recent years, particularly with the rapid development of its mRNA COVID-19 vaccine. This innovative approach not only contributed to the global pandemic response but also demonstrated the potential of new vaccine technologies.

Commitment to Sustainability:
Pfizer is committed to sustainability and has implemented numerous initiatives to reduce its environmental impact. The company engages in responsible sourcing, minimizing waste, and improving energy efficiency throughout its operations.

Conclusion:
Pfizer Inc. stands at the forefront of the pharmaceutical industry, driven by a vision to improve healthcare outcomes and enhance the quality of life for people around the globe. With a focus on innovation, collaboration, and sustainability, Pfizer continues to make significant contributions to the health and well-being of communities worldwide.


   Company Address: 66 Hudson Boulevard East New York 10001 NY
   Company Phone Number: 733-2323   Stock Exchange / Ticker: NYSE PFE


Customers Net Income grew by PFE's Customers Net Profit Margin grew to

81.85 %

4.76 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
IONS   -6.89%    
JNJ        4.76% 
MRK        1.87% 
OGN        0.07% 
TEVA   -2.66%    
VRTX        1.9% 
• View Complete Report
   



Business Update

XTANDI and Leuprolide A Pioneering Duo Slashing Prostate Cancer Mortality by 40%! ,

Published Mon, Oct 20 2025 8:19 AM UTC

In a groundbreaking revelation, Pfizer Inc. and Astellas Pharma U.S. Inc. have unveiled significant findings from the Phase 3 EMBARK study, heralding a new era in the treatment landscape for men grappling with advanced prostate cancer. The trial results indicate that the combination therapy of XTANDI (enzalutamide) and leuprolide reduces the risk of death by an impressive 40...

Business Update

Pfizer Showcases Innovations in Infectious Disease Research at IDWeek 2025 Amid Financial Pressures,

Published Mon, Oct 13 2025 1:25 PM UTC

Pfizer Inc. (NYSE: PFE) is set to showcase its latest advancements in the realm of respiratory health and infectious disease research at the upcoming IDWeek 2025 congress, taking place from October 19-22, 2025, in Atlanta, Georgia. The company is gearing up to present data derived from a total of 46 abstracts that encompass both company-led studies and collaborations with va...

Announcement

Advancements in mRNA Vaccine Technology Pfizer and BioNTech Gain FDA Approval for COVID-19 Vaccine and Enhance Influe...

Published Thu, Aug 28 2025 11:39 AM UTC

In a pivotal development in the ongoing battle against COVID-19, Pfizer Inc. and BioNTech SE have gained U.S. Food and Drug Administration (FDA) approval for their LP.8.1-adapted monovalent COVID-19 vaccine, COMIRNATY. Announced on August 27, 2025, this approval is significant as it extends vaccination eligibility to a critical demographic: adults aged 65 and older, along wi...

Partnership

Vepdegestrants Promise Redefining Advanced Breast Cancer Treatment Through Improved Progression-Free Survival,

Published Sat, May 31 2025 1:06 PM UTC

Innovative Treatment Advantage: Vepdegestrant s Role in Redefining Progression-Free Survival in ESR1-Mutant Advanced Breast Cancer The pursuit of improving therapeutic outcomes for advanced breast cancer has reached a significant milestone with the results from the Phase 3 VERITAC2 clinical trial, heralding a promising new era in oncology. Arvinas, Inc. (Nasdaq: ARVN) and P...

Business Update

Pfizers Sasanlimab Combination Therapy Shows Promising Results in Bladder Cancer amidst Development Setbacks,

Published Sun, Apr 27 2025 9:46 AM UTC

Pfizer s Sasanlimab Combination Significantly Improves Event-Free Survival in High-Risk Non-Muscle Invasive Bladder Cancer Pfizer Inc. (NYSE: PFE), a leading global biopharmaceutical company headquartered in New York, has announced promising results from a pivotal Phase 3 CREST trial involving their investigational anti-PD1 monoclonal antibody (mAb), sasanlimab. This trial t...




Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) 37.78
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 2.58
Price to Sales (Expected) -
Price to Book 1.92
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.64
Working Capital Ratio 1.35
Leverage Ratio (MRQ) 1.36
Total Debt to Equity 0.74
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.17

Per Share Current
Earnings (TTM) 0.76 $
Revenues (TTM) 11.18 $
Cash Flow (TTM) 0.01 $
Cash 3.66 $
Book Value 15 $
Dividend (TTM) 1.72 $

Efficiency Current
Revenue per Employee (TTM) 849,280
Net Income per Employee (TTM) 58,267
Receivable Turnover Ratio (TTM) 4.98
Inventory Turnover Ratio (TTM) 1.6
Asset Turnover Ratio (TTM) 0.31

Profitability Ratios Current
Gross Margin (MRQ) 72.78 %
Operating Margin (MRQ) 0 %
Net Margin (MRQ) -1.58 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 2.1 %
Return On Investment (TTM) 2.57 %
Return On Equity (TTM) 4.91 %
Dividend Yield 5.97 %
Pay out Ratio (TTM) 225.54 %



Pfizer Inc's Segments
Comirnaty    14.53 % of total Revenue
Paxlovid    6.56 % of total Revenue
Government and Government Sponsored Paxlovid and Comirnaty    10.38 % of total Revenue
Other Business Activities    2 % of total Revenue
Biopharma    97.99 % of total Revenue
U S    60.42 % of total Revenue
International Developed Markets    23.71 % of total Revenue
International Emerging Markets    15.87 % of total Revenue
Biopharma U S Commercial Division    53.19 % of total Revenue
Biopharma International Commercial Division    36.21 % of total Revenue
Biopharma Global Hospital and Biosimilars Division    8.59 % of total Revenue
Pfizer CentreOne    2 % of total Revenue
Total Alliance revenues    16.19 % of total Revenue
Royalty    2.74 % of total Revenue
Primary Care Biopharma    38.35 % of total Revenue
Primary Care Eliquis Biopharma    14.99 % of total Revenue
Primary Care Prevnar Family Biopharma    11.69 % of total Revenue
Primary Care Nurtec ODT Vydura Biopharma    2.44 % of total Revenue
Primary Care Comirnaty Biopharma    1.61 % of total Revenue
Primary Care Paxlovid Biopharma    1.29 % of total Revenue
Primary Care Abrysvo Biopharma    1.25 % of total Revenue
Primary Care FSME-IMMUN TicoVac Biopharma    0.56 % of total Revenue
Primary Care All other Primary Care Biopharma    4.53 % of total Revenue
Specialty Care Biopharma    20.34 % of total Revenue
Specialty Care Vyndaqel family Biopharma    11.09 % of total Revenue
Specialty Care Xeljanz Biopharma    1.25 % of total Revenue
Specialty Care Zavicefta Outside the U S and Canada Biopharma    1.04 % of total Revenue
Specialty Care Enbrel Outside the U S and Canada Biopharma    0.95 % of total Revenue
Specialty Care Octagam Biopharma    0.84 % of total Revenue
Specialty Care Genotropin Biopharma    0.64 % of total Revenue
Specialty Care Cibinqo Biopharma    0.53 % of total Revenue
Specialty Care All other Specialty Care Biopharma    4.01 % of total Revenue
Oncology Biopharma    26.48 % of total Revenue
Oncology Ibrance Biopharma    6.98 % of total Revenue
Oncology Padcev Biopharma    4.09 % of total Revenue
Oncology Xtandi Biopharma    3.07 % of total Revenue
Oncology Lorbrena Biopharma    2.11 % of total Revenue
Oncology Inlyta Biopharma    1.48 % of total Revenue
Oncology Adcetris Biopharma    1.31 % of total Revenue
Oncology Braftovi Mektovi Biopharma    1.2 % of total Revenue
Oncology Bosulif Biopharma    0.89 % of total Revenue
Oncology Tukysa Biopharma    0.84 % of total Revenue
Oncology Orgovyx Biopharma    0.75 % of total Revenue
Oncology Elrexfio Biopharma    0.55 % of total Revenue
Oncology Talzenna Biopharma    0.35 % of total Revenue
Oncology Tivdak Biopharma    0.23 % of total Revenue
Oncology All other Oncology Biopharma    2.6 % of total Revenue
Hospital and Biosimilars Biopharma    12.83 % of total Revenue
Hospital and Biosimilars Oncology Biosimilars Biopharma    2.83 % of total Revenue
Hospital and Biosimilars Sulperazon Outside the U S and Canada Biopharma    1.38 % of total Revenue
Hospital and Biosimilars Inflectra Biopharma    1.26 % of total Revenue
Hospital and Biosimilars Zithromax Biopharma    0.78 % of total Revenue
Hospital and Biosimilars All Other Hospital and Biosimilars Biopharma    6.59 % of total Revenue

  Pfizer Inc Outlook

On January 30 2024 the Pfizer Inc provided following guidance

Pfizer Inc. (NYSE: PFE) released its financial re...





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.